BioScrip receives early termination of HSR waiting period for Option Care deal
BioScrip provided an update on its proposed merger with Option Care Enterprises. The company received notification on April 8, 2019, that early termination of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 waiting period has been granted for the company's proposed merger with Option Care. The company expects to file the preliminary Option Care merger proxy statement the week of April 29, 2019 with the U.S. SEC. After the proxy statement is filed, management from both BioScrip and Option Care plan to conduct joint analyst and investor meetings. As part of the analyst and investor meetings, the company will file an investor presentation with the SEC that will include a business and merger update. The company will release its first quarter 2019 financial results after the proxy statement filing. The company continues to anticipate that its merger with Option Care will close in the second half of 2019.